Review
Rev Diabet Stud,
2010,
7(2):105-111 |
DOI 10.1900/RDS.2010.7.105 |
Pancreatic Stem/Progenitor Cells for the Treatment of Diabetes
Hirofumi Noguchi1,2
1Regenerative Research Islet Transplant Program, Baylor Research Institute, 1400 8th Avenue, Fort Worth, TX 76104, USA
2Institute of Biomedical Studies, Baylor University, Waco, TX 76798, USA
Manuscript submitted June 23, 2010; resubmitted July 20, 2010; accepted July 22, 2010.
Keywords: diabetes, pancreatic stem/progenitor cells, duct, pancreatic endoderm, beta-cell, islet, acinar, islet transplantation
Abstract
Patients with type 1 diabetes, and most patients with type 2 diabetes, have associated hyperglycemia due to the absence or reduction of insulin production by pancreatic β-cells. Surgical resection of the pancreas may also cause insulin-dependent diabetes depending on the size of the remaining pancreas. Insulin therapy has greatly improved the quality of life of diabetic patients, but this method is inaccurate and requires lifelong treatment that only mitigates the symptoms. The successes achieved over the last few decades by the transplantation of whole pancreas and isolated islets suggest that diabetes can be cured by the replenishment of deficient β-cells. These observations are proof-of-principle and have intensified interest in treating diabetes by cell transplantation, and by the use of stem cells. Pancreatic stem/progenitor cells could be one of the sources for the treatment of diabetes. Islet neogenesis, the budding of new islets from pancreatic stem/progenitor cells located in or near pancreatic ducts, has long been assumed to be an active process in the postnatal pancreas. Several in vitro studies have shown that insulin-producing cells can be generated from adult pancreatic ductal tissues. Acinar cells may also be a potential source for differentiation into insulin-producing cells. This review describes recent progress on pancreatic stem/progenitor cell research for the treatment of diabetes.
Fulltext:
HTML
, PDF
(257KB)
This article has been cited by other articles:
|
CXCR4 positive cell-derived Pdx1-high/Shh-low cells originated from embryonic stem cells improve the repair of pancreatic injury in mice
Yu T, Qing Q, Deng N, Min XH, Zhao LN, Li JY, Xia ZS, Chen QK
Cell Biol Int 2015. In press
|
|
|
Death signalobody: inducing conditional cell death in response to a specific antigen
Tone Y, Kawahara M, Kawaguchi D, Ueda H, Nagamune T
Hum Gene Ther Methods 2013. 24(3):141-150
|
|
|
Influences of the diabetes surgery on pancreatic β-cells mass
Martinez-Moreno JM, Garciacaballero M
Nutr Hosp 2013. 28(Suppl 2):88-94
|
|
|
Stem cell niches exposed to tobacco smoke
Jedrzejas M, Skowron K, Czekaj P
Przegl Lek 2012. 69(10):1063-1073
|
|
|
Protective effect of rat pancreatic progenitors cells expressing Pdx1 and nestin on islets survival and function in vitro and in vivo
Zhou SY, Zhang YS, Li Q, Zhang Y, Qi H, Zhou HX, Deng CY, Li FR
J Physiol Biochem 2012. 68(4):603-610
|
|
|
Effect of mesenchymal stem cell therapy on recovery of streptozotocin-induced diabetes mellitus in adult male albino rats: a histological and immunohistochemical study
Afifi NM
Egypt J Histol 2012. 35(3):458-469
|
|
|
Redox homeostasis in pancreatic β cells
Jezek P, Dlaskova A, Plecita-Hlavata L
Oxid Med Cell Longev 2012. 2012:932838
|
|
|
Hyperbaric oxygenation of UW solution positively impacts on the energy state of porcine pancreatic tissue
Stiegler P, Stadlbauer-Köllner V, Sereinigg M, Hackl F, Puntschart A, Schweiger M, Prenner G, Schaffellner S, Iberer F, Lackner C
Eur Surg 2011. 43(6):366-373
|
|
|
Enhancing cell therapies from the outside in: cell surface engineering using synthetic nanomaterials
Stephan MT, Irvine DJ
Nano Today 2011. 6(3):309-325
|
|
|
Stem cell therapy in diabetes mellitus: current trends
Sarath R, Rani VL
Int J Biomed Res 2011. 2(12):608-617
|
|
|
Recent progress in pancreatic islet transplantation
Kuise T, Noguchi H
World J Transplant 2011. 1(1):13-18
|
|
|